No products in the cart.
Target Pipelines
Subscribe to
our newsletters!
Showing 21–31 of 31 results
- March of 2020This report provides an overview of anti-FcRn therapeutic antibodies and proteins in development for treatment of IgG-mediated autoimmune diseases.€ 100.00
- April of 2019This report provides an overview of therapeutic proteins in development for treatment of arginine-dependent tumors or for enzyme replacement therapy.€ 75.00
- April of 2019This report provides an overview of CD40 agonistic antibodies, proteins or viral vectors in development for treatment of solid tumors as monotherapy or in combination therapy.€ 150.00
- March of 2019This Target Pipeline List provides an overview of biologic and chemical entities on the market or in development for treatment of hyperuricemia associated with gout or tumor lysis€ 150.00
- February of 2019This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.€ 100.00
- January of 2019This Target Pipeline List provides an overview of biologic and small molecule approaches to raise high density lipoprotein (HDL) for reduction of recurrent cardiovascular events.€ 100.00
- December of 2018This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.€ 75.00
- January of 2019This Target Pipeline List provides an overview of agonist antibodies and fusion proteins targeting death receptor 4 and/or 5 in development for treatment of cancer.€ 100.00
- January of 2019This Target Pipeline list provides an overview of antibody- and cell-based therapeutics targeting DLL3 in development for treatment of DLL3-overexpressing cancers.€ 50.00
- January of 2019This Target Pipeline List provides a pipeline overview of tau imaging agents in development for diagnosis of tauopathies and measurement of tau-targeted treatment effects€ 50.00
- January of 2019This Target Pipeline List provides a pipeline overview of EP4 receptor antagonists in development for treatment of cancer€ 50.00
